A Phase II single agent clinical trial in platinum-resistant ovarian cancer has also completed enrollment...The firm previously said it planned to raise $10 million of units comprising shares of common stock and warrants

Tolar noted that the biotech has "had significant interest from large pharma already...Each Series 5 preferred share is convertible at the option of the holder into 2,500 shares of common stock at a conversion price of 40 cents per share, for a total of 52.5 million shares...The financing came only days after abstracts were released for the upcoming American Society of Clinical Oncology meeting

Pharmasset granted the option in connection with its previously announced offering of 3.2 million shares of common stock at an offering price of $29 per share, which is expected to close May 19, subject to customary closing conditions. (See BioWorld Today, May 17, 2010...The company plans to use the funds to support several clinical trials

Cell Therapeutics Inc., of Seattle, entered agreements to exchange up to 60 million shares of common stock for up to $30 million aggregate outstanding principal amount of its 4 percent convertible senior subordinated notes due 2010...DARA has two clinical-stage candidates: KRN5500, which is in Phase II for neuropathic pain in cancer patients, and DB959, a dual PPAR delta/gamma agonist in Phase I development for Type II diabetes

AspenBio Pharma Inc., of Castle Rock, Colo., entered definitive agreements with certain new and existing institutional investors to sell an aggregate of about 2.4 million units, each consisting of one share of common stock and one warrant to purchase 0.285 shares of stock, for gross proceeds of about $10 million

Bedminster, N.J.-based NPS upped the previously planned base offering of 7.5 million shares to 9 million shares, to be sold at $5.50 each, with a 30-day option for underwriters to buy up to 1.35 million more shares of common stock to cover overallotments, if any...NPSP558 could be somewhat risky, too, since there hasn't been much clinical work done in its indication, but the replacement approach taken by NPS with the compound ought to make investors somewhat less nervous...Regpara, which is

Each share is convertible into shares of common stock equal to 1,000 plus any accrued and unpaid dividends, divided by $0.69, the closing price of the stock on the date of issuance...NovaDel Pharma Inc., of Bridgewater, N.J., entered a purchase agreement to raise approximately $1.5 million through the sale of 9 million shares of its common stock to institutional investors at a price of $0.165 per share

Proceeds will support clinical trials of nanobodies for thrombosis, osteoporosis, inflammation and cancer...BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., is raising about $18 million through the sale of about 10.4 million shares of common stock and warrants to purchase up to 5.2 million shares to investors Great Point Partners LLC and Deerfield Management Co...Genticel S/A (formerly BT Pharma S/A), of Toulouse, France, raised €13.1 million (US$17.7 million) in private equity to conduct a Phase

Pharmasset Inc., of Princeton, N.J., said the underwriter exercised its option to purchase an additional 230,400 shares of common stock to cover overallotments for proceeds of $4.1 million...Funds will be used to support clinical trials and in-licensing deals for product candidates or additional technologies and complementary business asset acquisitions. (See BioWorld Today, Jan. 29, 2010...Net proceeds are expected to go primarily toward business development and general working capital. #kicker123

Under the terms, the company agreed to sell 5.4 million shares of common stock priced at $1.02125 per share

We have established collaborations with two big pharma companies on that," Soula said...EntreMed Inc., of Rockville, Md., completed a registered direct offering of about 3.1 million shares of common stock priced at 80 cents apiece, resulting in gross proceeds of $2.5 million...ZymoGenetics Inc., of Seattle, said underwriters fully exercised their overallotment option to purchase an additional 2.1 million shares of common stock in connection to its previous public offering, bringing the total net

Clavis Pharma ASA, of Oslo, Norway, has received an unsecured loan of NOK20 million (US$3.2 million) from Innovation Norway to support the Phase III program with elacytarabine in patients with late-stage acute myeloid leukemia...Clavis Pharma is about to begin a 350-patient Phase III study in the U.S...The securities consist of one share of common stock and one warrant to purchase 0.5 of a share of stock for five years and one warrant to purchase 0.5 of a share of common stock for 18 months

And Regado is banking on big pharma's interest, particularly those firms developing oral Factor Xa inhibitors, such as New York firms Bristol-Myers Squibb Co...The company agreed to sell 2.55 million units - each consisting of one share of common stock, a five-year Series A warrant to purchase 0.35 of an additional share and a one-year Series B warrant to purchase 0.15 of an additional share - priced at $2 per unit

The company has conducted supplementary preclinical and clinical human pharmacological studies that it believes have bolstered the safety profile of eprotirome...Karo hopes to have a partner to take that program into the clinical phase...Novavax Inc., of Rockville, Md., closed a public offering of 6.8 million shares of common stock at $3.30 per share

We're very cognizant that big pharma is looking aggressively outside their own walls," Tregay said...Human Genome Sciences Inc., of Rockville, Md., is offering 12.5 million shares of common stock, with an additional 1,875 million offered to underwriters to cover any overallotments...Radient develops diagnostics and skin care products.

But he said a dry-eye product, still in the early stages of clinical development, would require "real marketing muscle" and a partnership would be "paramount to us" in that indication...Cardiome Pharma Corp., of Vancouver, British Columbia, reported the final results of its modified Dutch auction tender offer to purchase for cancellation up to $27.5 million of its common shares, which expired Oct. 13...Shares of Rexahn (AMEX:RNN) closed at 73 cents Monday, down 5 cents.

AspenBio Pharma Inc., of Castle Rock, Colo., closed its public offering of 5.155 million shares of common stock at $1.70 per share

In August, specialty pharma Cumberland Pharmaceuticals Inc., of Nashville, Tenn. - another company already pulling in revenues - made its $85 million debut. (See BioWorld Today, Aug. 12, 2009, and Oct. 2, 2009.) In other financings news...In an agreement with institutional investors, the firm agreed to sell 3.5 million shares of common stock priced at $1.27 per share...Net proceeds are expected to support clinical development programs and for general working capital purposes

AspenBio Pharma Inc., of Castle Rock, Colo., priced a public offering of 4.5 million shares of common stock at $1.70 each